| Outcome Measures: |
Primary: Part 1 SAD: Number of adverse events, Measured in number of events., From investigational medicinal product (IMP) administration (day 1) until end of study visit (day 8)|Part 2 PoP: CL/F,I1063,SD- Apparent serum clearance of NNC0363-1063 after a single dose, Measured in millilitre per hour\*kilogram (mL/\[h\*kg\])., From IMP administration at day 1 up to 7 days|Part 3 MAD: Number of adverse events, Measured in number of events., From IMP administration at day 1 until day of the end of study visit at day 15 | Secondary: Part 1 SAD: Number of hypoglycaemic episodes, Measured in number of episodes., From investigational medicinal product (IMP) administration (day 1) until end of study visit (day 8)|Part 1 SAD: AUC0-inf,I1063,SD: Area under the serum NNC0363-1063 concentration-time curve from 0 to infinity after a single dose, Measured in hours\*picomoles per litre(h\*pmol/L)., Up to 7 days|Part 1 SAD: AUC,I1063,SD- Area under the serum NNC0363-1063 concentration time curve after a single dose, Measured in h\*pmol/L., Up to 2 days|Part 1 SAD: Cmax,I1063,SD- Maximum observed serum NNC0363-1063 concentration after a single dose, Measured in picomoles per litre (pmol/L)., Up to 7 days|Part 2 PoP: AUC0-inf,I1063,SD: Area under the serum NNC0363-1063 concentration-time curve from 0 to infinity after a single dose, Measured in h\*pmol/L., Up to 7 days|Part 2 PoP: AUC,I1063,SD- Area under the serum NNC0363-1063 concentration time curve after a single dose, Measured in h\*pmol/L., Up to 2 days|Part 2 PoP: Cmax,I1063,SD- Maximum observed serum NNC0363-1063 concentration after a single dose, Measured in pmol/L., Up to 7 days|Part 3 MAD: Number of hypoglycaemic episodes, Measured in number of episodes., From IMP administration (day 1) until day of the end of study visit (day 15)|Part 3 MAD: AUCτ,I1063,SS: Area under the serum NNC0363-1063 concentration-time curve during one dosing interval at steady state, Measured in h\*pmol/L., At day 5 and 8|Part 3 MAD: Cmax,I1063,SS- Maximum observed serum NNC0363-1063 concentration during one dosing interval at steady state, Measured in pmol/L., At day 5 and 8
|
